329 related articles for article (PubMed ID: 23610611)
1. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.
Sonbol MB; Firwana B; Zarzour A; Morad M; Rana V; Tiu RV
Ther Adv Hematol; 2013 Feb; 4(1):15-35. PubMed ID: 23610611
[TBL] [Abstract][Full Text] [Related]
2. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
4. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
[TBL] [Abstract][Full Text] [Related]
5. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
[TBL] [Abstract][Full Text] [Related]
6. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.
Vainchenker W; Leroy E; Gilles L; Marty C; Plo I; Constantinescu SN
F1000Res; 2018; 7():82. PubMed ID: 29399328
[TBL] [Abstract][Full Text] [Related]
8. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.
Adesola AA; Cozma MA; Chen YF; Srichawla BS; Găman MA
World J Hepatol; 2023 Nov; 15(11):1188-1195. PubMed ID: 38075009
[TBL] [Abstract][Full Text] [Related]
9. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
10. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
12. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
Mesa RA; Scherber RM; Geyer HL
Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
[TBL] [Abstract][Full Text] [Related]
15. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
16. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
17. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
Mascarenhas J; Mughal TI; Verstovsek S
Curr Med Chem; 2012; 19(26):4399-413. PubMed ID: 22830345
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
